Smruthi Organics Limited has filed its quarterly compliance certificate with stock exchanges, fulfilling mandatory regulatory requirements under SEBI Depositories and Participants Regulations for the quarter ended 31st March, 2026.

Regulatory Filing Details

The company submitted the certificate dated 07th April, 2026 to both BSE Limited and Metropolitan Stock Exchange of India Ltd. The filing pertains to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Compliance Confirmation

Adroit Corporate Services Pvt. Ltd., serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on 01st April 2026. The certificate confirms several key compliance aspects:

• Securities received from depository participants for dematerialisation during the quarter were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation have been mutilated and cancelled after due verification
• Depository names have been substituted in the register of members as registered owners within the prescribed 15-day period

Corporate Governance

The filing was signed by Urvashi D. Khanna, Company Secretary & Compliance Officer, demonstrating the company's commitment to maintaining proper corporate governance standards. The certificate submission ensures transparency in the dematerialisation process and adherence to securities market regulations.

This quarterly compliance filing represents standard regulatory practice for listed companies, ensuring proper maintenance of shareholder records and adherence to depository regulations during the reporting period.

Smruthi organics Limited has achieved a major regulatory milestone with the receipt of a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM). This certification completes the regulatory approval process that began with the company's successful EU GMP compliance inspection for its Amlodipine Besilate manufacturing operations.

EDQM Inspection and Certification Process

The regulatory journey began with a comprehensive EDQM inspection conducted at the company's flagship API manufacturing facility, Unit II, located in Solapur, Maharashtra. The evaluation took place over three days from 27 August 2025 to 29 August 2025, which resulted in an Attestation of Inspection confirming compliance with stringent European Good Manufacturing Practice standards.

CEP Certificate Significance

The CEP certifies that the quality of the Amlodipine Besilate substance complies with the requirements of the European Pharmacopoeia. This certification enables the company to supply this product to pharmaceutical manufacturers in European markets and other regions that recognize the CEP certification. The certificate represents the successful completion of the EDQM regulatory approval process that was initiated following the positive inspection outcome.

Market Expansion Opportunities

This regulatory achievement significantly strengthens the company's position in regulated European and allied markets while enhancing credibility with global customers. The CEP certification is expected to support several key business objectives:

• Direct supply capabilities to European pharmaceutical manufacturers
• Enhanced market access in regions recognizing CEP certification
• Improved competitive positioning in regulated export markets
• Strengthened regulatory portfolio for future product approvals

Regulatory Compliance and Future Outlook

The company has formally notified the stock exchanges about receiving the CEP certificate under Regulation 30 of SEBI (LODR) Regulations, 2015. This milestone strengthens the company's regulatory portfolio and demonstrates its commitment to maintaining the highest quality manufacturing standards. The successful completion of the EDQM certification process positions Smruthi Organics Limited to capitalize on expanded opportunities in the European pharmaceutical market while continuing its focus on regulatory excellence and long-term value creation for stakeholders.